

# Planned filings 2015 to ≥ 2019

2015	2016	2017	2018	≥ 2019	
<b>BKM120</b> mBC ER+ AI resistant/mTOR naive	<b>BYM338</b> sIBM <sup>5</sup>	<b>KAE609</b> Malaria	<b>INC280</b> NSLCL <sup>14</sup>	<b>BAF312</b> Multiple sclerosis	<b>LIK066</b> Type II diabetes
<b>LCQ908</b> FCS <sup>1</sup>	<b>CTL019</b> Acute lymphoblastic leukemia	<b>LCI699</b> Cushing's disease	<b>Afinitor®</b> DLBCL <sup>12</sup>	<b>BCT197</b> COPD <sup>16</sup>	<b>LJM716</b> Solid tumors
<b>PKC412</b> AML <sup>2</sup>	<b>Fovista®</b> Wet AMD	<b>ACZ885</b> Sec. prev. cv events <sup>11</sup>	<b>Lucentis®</b> ROP <sup>15</sup>	<b>BGJ398</b> Solid tumors	<b>QAW039</b> Asthma
<b>Afinitor®</b> Non-functioning GI and Lung NET <sup>3</sup>	<b>LEE011</b> HR+, HER2(-) advanced breast cancer (postmenopausal women)	<b>CTL019</b> DLBCL <sup>12</sup>	<b>LEE011</b> HR+, HER2(-) advanced breast cancer (premenopausal women)	<b>BGS649</b> OHH <sup>17</sup>	<b>QAX576</b> Allergic diseases
<b>Cosentyx™</b> Ankylosing spondylitis	<b>MEK162*</b> NRAS mutant melanoma	<b>Gilenya®</b> CIDP <sup>13</sup>	<b>LEE011</b> Solid tumors	<b>BYL719</b> Solid tumors	<b>QGE031</b> Asthma
<b>Cosentyx™</b> Psoriatic arthritis	<b>MEK162* + LGX818</b> BRAF mutant melanoma	<b>Zykadia™</b> ALK+advanced NSCLC <sup>14</sup> (first line, treatment naive)		<b>CAD106</b> Alzheimer's disease	<b>BKM120</b> Solid tumors
<b>PKC412</b> ASM <sup>4</sup>	<b>RLX030</b> Acute heart failure			<b>CJM112</b> Immune disorders	<b>BYM338</b> Hip fracture
	<b>Afinitor®</b> TSC <sup>6</sup> seizures			<b>EGF816</b> Solid tumors	<b>BYM338</b> Sarcopenia
	<b>BKM120</b> mBC ER+ post AI and mTOR inhibitor			<b>FCR001</b> Renal transplantation	<b>LCZ696</b> Heart failure (PEF) <sup>18</sup>
	<b>Ilaris®</b> Hereditary periodic fevers			<b>HSC835</b> Stem cell transplantation	<b>MEK162*</b> Solid tumors
	<b>Lucentis®</b> CNV and ME <sup>7</sup>			<b>KAF156</b> Malaria	<b>QAW039</b> Atopic dermatitis
	<b>MEK162*</b> LGSOC <sup>8</sup>			<b>LGX818</b> Solid tumors	
	<b>Tasigna®</b> CML treatment free remission				
	<b>Tekturna®</b> Heart failure <sup>9</sup>				
	<b>Signifor® LAR<sup>10</sup></b> Cushing's disease				

**New molecule**

**New indication**

**New formulation**

<sup>1</sup> Familial chylomicronemia syndrome

<sup>2</sup> Acute myeloid leukemia

<sup>3</sup> Neuroendocrine tumors

<sup>4</sup> Aggressive systemic mastocytosis

<sup>5</sup> Sporadic inclusion body myositis

<sup>6</sup> Tuberous sclerosis complex

<sup>7</sup> Choroidal neovascularization (CNV) and macular edema (ME) secondary to conditions other than macular degeneration, diabetic macular edema, retinal vein occlusion and pathologic myopia

<sup>8</sup> Low-grade serous ovarian cancer

<sup>9</sup> Reduction of CV death/hospitalization in chronic heart failure patients

<sup>10</sup> Long-acting release

<sup>11</sup> Secondary prevention of cardiovascular events

<sup>12</sup> Diffuse large B-cell lymphoma

<sup>13</sup> Chronic inflammatory demyelinating polyradiculoneuropathy

<sup>14</sup> Non-small cell lung cancer

<sup>15</sup> Retinopathy of prematurity

<sup>16</sup> Chronic obstructive pulmonary disease

<sup>17</sup> Obese hypogonadotropic hypogonadism

<sup>18</sup> Preserved ejection fraction

\* MEK162 rights to be returned to Array BioPharma Inc. which is conditional on the closing of the portfolio transformation transaction with GSK